Nervgen Pharma (NGEN) Receivables (2024 - 2026)

Nervgen Pharma (NGEN) posted quarterly Receivables of $68206.3 for Q1 2026, up 17.68% quarter-over-quarter from $57958.5 in Q4 2025.

Nervgen Pharma (NGEN) Receivables (2024 - 2026) Analysis & Trends

Nervgen Pharma (NGEN) has reported Receivables for 3 consecutive years, with $68206.3 the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $68206.3; the TTM figure through Mar 2026 stood at $68206.3 (changed N/A YoY), while the FY2025 annual figure was $57958.5, down 80.5% from the prior year.
Receivables rose to $68206.3 in Q1 2026 per NGEN's latest filing, from $57958.5 in the prior quarter.
Across five years, Receivables topped out at $297292.9 in Q4 2024 and bottomed at $57958.5 in Q4 2025.
Historically, Receivables has averaged $141152.5 across 3 years, with a median of $68206.3 in 2026.
On a YoY basis, Receivables climbed as much as 80.5% in 2025 and fell as far as 80.5% in 2025.
Nervgen Pharma's Receivables stood at $297292.9 in 2024, then slumped by 80.5% to $57958.5 in 2025, then increased by 17.68% to $68206.3 in 2026.
Business Quant data shows NGEN's Receivables at $68206.3 in Q1 2026, $57958.5 in Q4 2025, and $297292.9 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	Nervgen Pharma	161.78 Mn	161.78 Mn	-	144,755.67

Download Data